Chongqing Zhifei Biological Products Co., Ltd. (SHE:300122)

Market Cap	45.17B
Revenue (ttm)	10.91B
Net Income (ttm)	-1.31B
Shares Out	2.39B
EPS (ttm)	-0.55
PE Ratio	n/a
Forward PE	13.12
Dividend	0.20 (1.06%)
Ex-Dividend Date	Dec 25, 2024

Volume	19,706,886
Average Volume	11,172,903
Open	18.90
Previous Close	18.87
Day's Range	18.88 - 19.44
52-Week Range	18.70 - 27.80
Beta	0.77
RSI	31.81
Earnings Date	Apr 28, 2026

About SHE:300122

Chongqing Zhifei Biological Products Co., Ltd. engages in the research and development, production, marketing, distribution, import, and export of vaccines in China. The company offers Recombinant Novel Coronavirus Vaccine (CHO Cell); Recombinant Mycobacterium Tuberculosis Fusion Protein under the Ekear brand; Haemophilus Influenzae Type b Vaccine under the XiFeiBei brand; ACYW135 Meningococcal Polysaccharide Vaccine under the Menwayc brand; Mycobacterium Vaccae for Injection under the Vaccae brand; Meningococcal Group A and Group C Polysacchar...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2002
• Employees: 7,220
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 300122

Financial Performance

In 2024, SHE:300122's revenue was 26.07 billion, a decrease of -50.74% compared to the previous year's 52.92 billion. Earnings were 2.02 billion, a decrease of -74.99%.